Related Experiment Video
Updated: Nov 8, 2025
08:36
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
7.8K
CAR-macrophage: A new immunotherapy candidate against solid tumors
Yizhao Chen1, Zhiying Yu2, Xuewen Tan1
1Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Hefei, China.
Summary
Chimeric antigen receptor (CAR)-T cell therapy is effective for blood cancers but not solid tumors. Researchers are exploring CAR-modified macrophages (CAR-M) to target solid tumors due to macrophages' ability to infiltrate tumor tissues.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows promise for hematological malignancies.
- Solid tumor treatment remains a significant challenge for current immunotherapies.
- Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment and promote tumor growth and immune evasion.
Purpose of the Study:
- To review recent advancements in CAR-modified macrophage (CAR-M) therapy for solid tumors.
- To summarize the limitations and future potential of CAR-M-based treatments.
Main Methods:
- Review of recent scientific literature on CAR-M therapy.
- Analysis of CAR-M interactions within the tumor microenvironment.
Main Results:
- Macrophages, particularly TAMs, are key cellular components in the tumor microenvironment.
- CAR-M therapy is being investigated as a novel approach to overcome solid tumor treatment challenges.
- Macrophages' ability to infiltrate solid tumors and interact with various cellular components makes them promising therapeutic candidates.
Conclusions:
- CAR-M therapy represents a potential strategy to enhance the efficacy of immunotherapy against solid tumors.
- Further research is needed to address the shortcomings and optimize the application of CAR-M for clinical use.
